{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:18:06Z","timestamp":1788481086991,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41401-023-01097-4","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T03:46:08Z","timestamp":1684986368000},"page":"2113-2124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition"],"prefix":"10.1038","volume":"44","author":[{"given":"Lei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai-shuai","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-ze","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-fen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"1097_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nsmb.2669","volume":"20","author":"L Di Croce","year":"2013","unstructured":"Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol. 2013;20:1147\u201355.","journal-title":"Nat Struct Mol Biol"},{"key":"1097_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.","journal-title":"J Hematol Oncol"},{"key":"1097_CR3","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","volume":"80","author":"ML Eich","year":"2020","unstructured":"Eich ML, Athar M, Ferguson JE 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80:5449\u201358.","journal-title":"Cancer Res"},{"key":"1097_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective Inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13:842.","journal-title":"Mol Cancer Ther"},{"key":"1097_CR5","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433\u201342.","journal-title":"Lancet Oncol"},{"key":"1097_CR6","doi-asserted-by":"crossref","unstructured":"Italiano A, Soria J-C, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology. 2018;19:649\u201359.","DOI":"10.1016\/S1470-2045(18)30145-1"},{"key":"1097_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108\u201312.","journal-title":"Nature"},{"key":"1097_CR8","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-20-2017","volume":"80","author":"SV Torti","year":"2020","unstructured":"Torti SV, Torti FM. Iron and Cancer: 2020 Vision. Cancer Res. 2020;80:5435\u201348.","journal-title":"Cancer Res"},{"key":"1097_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ijms20010095","volume":"20","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yu L, Ding J, Chen Y. Iron metabolism in cancer. Int J Mol Sci. 2018;20:95.","journal-title":"Int J Mol Sci"},{"key":"1097_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00350-9","volume":"8","author":"YF Wang","year":"2017","unstructured":"Wang YF, Zhang J, Su Y, Shen YY, Jiang DX, Hou YY, et al. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun. 2017;8:274.","journal-title":"Nat Commun"},{"key":"1097_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10534-017-0037-7","volume":"30","author":"HH Kazan","year":"2017","unstructured":"Kazan HH, Urfali-Mamatoglu C, Gunduz U. Iron metabolism and drug resistance in cancer. Biometals. 2017;30:629\u201341.","journal-title":"Biometals"},{"key":"1097_CR12","doi-asserted-by":"publisher","first-page":"e1704007","DOI":"10.1002\/adma.201704007","volume":"30","author":"Z Shen","year":"2018","unstructured":"Shen Z, Song J, Yung BC, Zhou Z, Wu A, Chen X. Emerging strategies of cancer therapy based on ferroptosis. Adv Mater. 2018;30:e1704007\u2013e.","journal-title":"Adv Mater"},{"key":"1097_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"1097_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247\u201350.","journal-title":"Nature"},{"key":"1097_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830\u201349.","journal-title":"Cancer Cell"},{"key":"1097_CR16","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1158\/1538-7445.AM2022-5436","volume":"82","author":"XX Chen","year":"2022","unstructured":"Chen XX, Shen QQ, Zhao Z, Fang YF, Yang JY, Gao YL, et al. Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1\/2 with potent anti-tumor activities. Cancer Res. 2022;82:5436.","journal-title":"Cancer Res"},{"key":"1097_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","volume":"175","author":"X Huang","year":"2018","unstructured":"Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell. 2018;175:186\u201399.e19.","journal-title":"Cell"},{"key":"1097_CR18","doi-asserted-by":"crossref","unstructured":"Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X, et al. Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. Cancer Cell. 2016;30:243\u201356.","DOI":"10.1016\/j.ccell.2016.06.021"},{"key":"1097_CR19","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.7150\/thno.59092","volume":"11","author":"M Morales","year":"2021","unstructured":"Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics. 2021;11:8412\u201329.","journal-title":"Theranostics"},{"key":"1097_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-med-043021-032816","volume":"74","author":"E Nemeth","year":"2023","unstructured":"Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023;74:261\u201377.","journal-title":"Annu Rev Med"},{"key":"1097_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","volume":"1823","author":"T Ganz","year":"2012","unstructured":"Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823:1434\u201343.","journal-title":"Biochim Biophys Acta"},{"key":"1097_CR22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fphar.2017.00992","volume":"8","author":"B Lu","year":"2018","unstructured":"Lu B, Chen XB, Ying MD, He QJ, Cao J, Yang B. The role of ferroptosis in cancer development and treatment response. Front Pharmacol. 2018;8:992.","journal-title":"Front Pharmacol"},{"key":"1097_CR23","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/ptr.6971","volume":"35","author":"H Yang","year":"2021","unstructured":"Yang H, Said AM, Huang H, Papa APD, Jin G, Wu S, et al. Chlorogenic acid depresses cellular bioenergetics to suppress pancreatic carcinoma through modulating c-Myc-TFR1 axis. Phytother Res. 2021;35:2200\u201310.","journal-title":"Phytother Res"},{"key":"1097_CR24","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/MCB.26.6.2373-2386.2006","volume":"26","author":"KA O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol. 2006;26:2373\u201386.","journal-title":"Mol Cell Biol"},{"key":"1097_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03790-w","volume":"12","author":"Y Lu","year":"2021","unstructured":"Lu Y, Yang Q, Su Y, Ji Y, Li G, Yang X, et al. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma. Cell Death Dis. 2021;12:511.","journal-title":"Cell Death Dis"},{"key":"1097_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41586-019-1426-6","volume":"572","author":"J Wu","year":"2019","unstructured":"Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572:402\u20136.","journal-title":"Nature"},{"key":"1097_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.phymed.2015.08.002","volume":"22","author":"E Ooko","year":"2015","unstructured":"Ooko E, Saeed ME, Kadioglu O, Sarvi S, Colak M, Elmasaoudi K, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015;22:1045\u201354.","journal-title":"Phytomedicine"},{"key":"1097_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.freeradbiomed.2020.10.307","volume":"162","author":"LJ Tang","year":"2021","unstructured":"Tang LJ, Zhou YJ, Xiong XM, Li NS, Zhang JJ, Luo XJ, et al. Ubiquitin-specific protease 7 promotes ferroptosis via activation of the p53\/TfR1 pathway in the rat hearts after ischemia\/reperfusion. Free Radic Biol Med. 2021;162:339\u201352.","journal-title":"Free Radic Biol Med"},{"key":"1097_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"1097_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22336-4","volume":"12","author":"CM Bebber","year":"2021","unstructured":"Bebber CM, Thomas ES, Stroh J, Chen Z, Androulidaki A, Schmitt A, et al. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nat Commun. 2021;12:2048.","journal-title":"Nat Commun"},{"key":"1097_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688\u201392.","journal-title":"Nature"},{"key":"1097_CR32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593:586\u201390.","journal-title":"Nature"},{"key":"1097_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41392-021-00656-7","volume":"6","author":"F Wang","year":"2021","unstructured":"Wang F, Min J. DHODH tangoing with GPX4 on the ferroptotic stage. Signal Transduct Target Ther. 2021;6:244.","journal-title":"Signal Transduct Target Ther"},{"key":"1097_CR34","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1158\/0008-5472.CAN-16-1979","volume":"77","author":"S Zhu","year":"2017","unstructured":"Zhu S, Zhang Q, Sun X, Zeh HJ 3rd, Lotze MT, Kang R, et al. HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res. 2017;77:2064\u201377.","journal-title":"Cancer Res"},{"key":"1097_CR35","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S254995","volume":"13","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y. The role of erastin in ferroptosis and its prospects in cancer therapy. Onco Targets Ther. 2020;13:5429\u201341.","journal-title":"Onco Targets Ther"},{"key":"1097_CR36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/10428194.2021.2015588","volume":"63","author":"Y Lu","year":"2022","unstructured":"Lu Y, Zhao YL, Xiong M, Sun RJ, Cao XY, Wei ZJ, et al. Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study. Leuk Lymphoma. 2022;63:1211\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1097_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/0008-5472.CAN-21-0218","volume":"82","author":"J Devin","year":"2022","unstructured":"Devin J, Ca\u00f1eque T, Lin YL, Mondoulet L, Veyrune JL, Abouladze M, et al. Targeting cellular iron homeostasis with ironomycin in diffuse large B-cell lymphoma. Cancer Res. 2022;82:998\u20131012.","journal-title":"Cancer Res"},{"key":"1097_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0762-x","volume":"21","author":"S Genta","year":"2019","unstructured":"Genta S, Pirosa MC, Stathis A. BET and EZH2 inhibitors: novel approaches for targeting cancer. Curr Oncol Rep. 2019;21:13.","journal-title":"Curr Oncol Rep."},{"key":"1097_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0148-5","volume":"6","author":"R Tremblay-LeMay","year":"2018","unstructured":"Tremblay-LeMay R, Rastgoo N, Pourabdollah M, Chang H. EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomark Res. 2018;6:34.","journal-title":"Biomark Res"},{"key":"1097_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1158\/1541-7786.MCR-13-0546","volume":"12","author":"G Deb","year":"2014","unstructured":"Deb G, Singh AK, Gupta S. EZH2: not EZHY (easy) to deal. Mol Cancer Res. 2014;12:639\u201353.","journal-title":"Mol Cancer Res"},{"key":"1097_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","volume":"16","author":"D Sermer","year":"2019","unstructured":"Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16:494\u2013507.","journal-title":"Nat Rev Clin Oncol"},{"key":"1097_CR42","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/cas.13326","volume":"108","author":"D Honma","year":"2017","unstructured":"Honma D, Kanno O, Watanabe J, Kinoshita J, Hirasawa M, Nosaka E, et al. Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 2017;108:2069\u201378.","journal-title":"Cancer Sci"},{"key":"1097_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.omto.2020.01.003","volume":"16","author":"A Campisi","year":"2020","unstructured":"Campisi A, Bonfanti R, Raciti G, Bonaventura G, Legnani L, Magro G, et al. Gene silencing of transferrin-1 receptor as a potential therapeutic target for human follicular and anaplastic thyroid cancer. Mol Ther Oncolytics. 2020;16:197\u2013206.","journal-title":"Mol Ther Oncolytics"},{"key":"1097_CR44","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2174\/1871530318666180605094706","volume":"18","author":"AA Hagag","year":"2018","unstructured":"Hagag AA, Badraia IM, Abdelmageed MM, Hablas NM, Hazzaa SME, Nosair NA. Prognostic value of transferrin receptor-1 (CD71) expression in acute lymphoblastic leukemia. Endocr Metab Immune Disord Drug Targets. 2018;18:610\u20137.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"1097_CR45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1084\/jem.20091488","volume":"207","author":"C Callens","year":"2010","unstructured":"Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010;207:731\u201350.","journal-title":"J Exp Med"},{"key":"1097_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1006\/bbrc.1993.2536","volume":"197","author":"K Barabas","year":"1993","unstructured":"Barabas K, Faulk WP. Transferrin receptors associate with drug resistance in cancer cells. Biochem Biophys Res Commun. 1993;197:702\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1097_CR47","doi-asserted-by":"publisher","first-page":"12151","DOI":"10.1074\/jbc.272.18.12151","volume":"272","author":"CR Chitambar","year":"1997","unstructured":"Chitambar CR, Wereley JP. Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium\/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. J Biol Chem. 1997;272:12151\u20137.","journal-title":"J Biol Chem"},{"key":"1097_CR48","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1462-5822.2005.00519.x","volume":"7","author":"RA Bonnah","year":"2005","unstructured":"Bonnah RA, Hoelter J, Steeghs L, Enns CA, So M, Muckenthaler MU. Lipooligosaccharide-independent alteration of cellular homeostasis in Neisseria meningitidis-infected epithelial cells. Cell Microbiol. 2005;7:869\u201385.","journal-title":"Cell Microbiol"},{"key":"1097_CR49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1042\/BJ20120625","volume":"449","author":"NS Kenneth","year":"2013","unstructured":"Kenneth NS, Mudie S, Naron S, Rocha S. TfR1 interacts with the IKK complex and is involved in IKK-NF-\u03baB signalling. Biochem J. 2013;449:275\u201384.","journal-title":"Biochem J"},{"key":"1097_CR50","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s10753-021-01609-6","volume":"45","author":"J Weng","year":"2022","unstructured":"Weng J, Chen L, Liu H, Yang XP, Huang L. Ferroptosis markers predict the survival, immune infiltration, and ibrutinib resistance of diffuse large B cell lymphoma. Inflammation. 2022;45:1146\u201361.","journal-title":"Inflammation"},{"key":"1097_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23902-6","volume":"12","author":"D Chen","year":"2021","unstructured":"Chen D, Chu B, Yang X, Liu Z, Jin Y, Kon N, et al. iPLA2\u03b2-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nat Commun. 2021;12:3644.","journal-title":"Nat Commun"},{"key":"1097_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","volume":"26","author":"WS Yang","year":"2016","unstructured":"Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165\u201376.","journal-title":"Trends Cell Biol"},{"key":"1097_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-2-18","volume":"2","author":"H Mizuno","year":"2009","unstructured":"Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genom. 2009;2:18.","journal-title":"BMC Med Genom"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01097-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:04:56Z","timestamp":1696233896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01097-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1038\/s41401-023-01097-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JD is the Chairman of Haihe Biopharma Co., Ltd. No competing interests is disclosed for rest of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}